All News
JAK Inhibitor Misses Endpoint in Safety Study. Now What?
Pfizer announced results Wednesday from its FDA-mandated postmarketing safety study of tofacitinib (Xeljanz), and they don't bode well for the drug and possibly others in its class.
Read Article
Urate Lowering Therapy During Acute Gout
Acute gout has its well defined protocols, and most state that urate lowering therapy (ULT) should be continued; but does ULT affect outcomes in an acute gout attack?
Read Article
Rheumatologists Rank 2nd in Physician Burnout
The 2021 Medscape Survey on Physician burnout ranks rheumatology second, just behind Critical Care medicine.
The survey included over 12,000 physcians from 20 specialties. While 42% of MDs claimed to be burnt-out, Rheumatologists claimed this 50% of the time. The top 3 this year were Critical care (51%), Rheumatology (50%) and infectious disease (49%).
Links:
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Links:
The risk of RA was studied in cohort of 14,463 endometriosis pts. RA risk was higher in those w/ endometriosis [adjusted HR 1.75), and also w/ age ≥45 years (adj HR 1.50) or with autoimmune disease (adj HR 6.99). https://t.co/sPouzyFI3H https://t.co/lDjSgLxXfV
Links:
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Links:
Links:
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
